Abstract:Targeted ultrasound contrast agents can be prepared by some specific bioconjugation techniques. The biotin-avidin complex is an extremely useful noncovalent binding system, but the system might induce immunogenic side effects in human bodies. Previous proposed covalently conjugated systems suffered from low conjugation efficiency and complex procedures. In this study, we propose a covalently conjugated nanobubble coupling with nucleic acid ligands, aptamers, for providing a higher specific affinity for ultraso… Show more
“…For example, Lanza et al used a 30MHz intravascular ultrasound system to detect thrombi with a targeted perfluorocarbon emulsion based contrast agent (250nm) 22 . Wang et al used a custom-made 40MHz transducer to image nanobubbles (485nm) targeting to CCRF-CEM cells in an ex vivo model 23 . Efforts have also been made to decrease the shell stiffness by incorporating surfactant in order to decrease the detection frequency for nanobubbles, as described in detail below 18 .…”
Section: Physics and Theory Behind Ultrasound And Its Contrast Agentsmentioning
confidence: 99%
“…Although the mechanism is not fully understood, it has been postulated that the shell bending modulus resists increases in curvature below 1 μm, producing only a small number of nanobubbles 39 . Nanobubble formulations have thus been obtained by extraction of this nanometer subpopulation from microbubble solutions based on their buoyancy by centrifugation 23, 40-45 . Although this method produces a relatively small nanobubble yield, it has been demonstrated that these nanobubbles are capable of extravasating the leaky vasculature in tumors and improving signal intensity under diagnostic ultrasound 42-44 .…”
Section: Next Generation Nano Agents In Cancer Detectionmentioning
Current commercially available ultrasound contrast agents are gas-filled, lipid- or protein-stabilized microbubbles larger than 1 μm in diameter. Because the signal generated by these agents is highly dependent on their size, small yet highly echogenic particles have been historically difficult to produce. This has limited the molecular imaging applications of ultrasound to the blood pool. In the area of cancer imaging, microbubble applications have been constrained to imaging molecular signatures of tumor vasculature and drug delivery enabled by ultrasound-modulated bubble destruction. Recently, with the rise of sophisticated advancements in nanomedicine, ultrasound contrast agents, which are an order of magnitude smaller (100-500 nm) than their currently utilized counterparts, have been undergoing rapid development. These agents are poised to greatly expand the capabilities of ultrasound in the field of targeted cancer detection and therapy by taking advantage of the enhanced permeability and retention phenomenon of many tumors and can extravasate beyond the leaky tumor vasculature. Agent extravasation facilitates highly sensitive detection of cell surface or microenvironment biomarkers, which could advance early cancer detection. Likewise, when combined with appropriate therapeutic agents and ultrasound-mediated deployment on demand, directly at the tumor site, these nanoparticles have been shown to contribute to improved therapeutic outcomes. Ultrasound's safety profile, broad accessibility and relatively low cost make it an ideal modality for the changing face of healthcare today. Aided by the multifaceted nano-sized contrast agents and targeted theranostic moieties described herein, ultrasound can considerably broaden its reach in future applications focused on the diagnosis and staging of cancer.
“…For example, Lanza et al used a 30MHz intravascular ultrasound system to detect thrombi with a targeted perfluorocarbon emulsion based contrast agent (250nm) 22 . Wang et al used a custom-made 40MHz transducer to image nanobubbles (485nm) targeting to CCRF-CEM cells in an ex vivo model 23 . Efforts have also been made to decrease the shell stiffness by incorporating surfactant in order to decrease the detection frequency for nanobubbles, as described in detail below 18 .…”
Section: Physics and Theory Behind Ultrasound And Its Contrast Agentsmentioning
confidence: 99%
“…Although the mechanism is not fully understood, it has been postulated that the shell bending modulus resists increases in curvature below 1 μm, producing only a small number of nanobubbles 39 . Nanobubble formulations have thus been obtained by extraction of this nanometer subpopulation from microbubble solutions based on their buoyancy by centrifugation 23, 40-45 . Although this method produces a relatively small nanobubble yield, it has been demonstrated that these nanobubbles are capable of extravasating the leaky vasculature in tumors and improving signal intensity under diagnostic ultrasound 42-44 .…”
Section: Next Generation Nano Agents In Cancer Detectionmentioning
Current commercially available ultrasound contrast agents are gas-filled, lipid- or protein-stabilized microbubbles larger than 1 μm in diameter. Because the signal generated by these agents is highly dependent on their size, small yet highly echogenic particles have been historically difficult to produce. This has limited the molecular imaging applications of ultrasound to the blood pool. In the area of cancer imaging, microbubble applications have been constrained to imaging molecular signatures of tumor vasculature and drug delivery enabled by ultrasound-modulated bubble destruction. Recently, with the rise of sophisticated advancements in nanomedicine, ultrasound contrast agents, which are an order of magnitude smaller (100-500 nm) than their currently utilized counterparts, have been undergoing rapid development. These agents are poised to greatly expand the capabilities of ultrasound in the field of targeted cancer detection and therapy by taking advantage of the enhanced permeability and retention phenomenon of many tumors and can extravasate beyond the leaky tumor vasculature. Agent extravasation facilitates highly sensitive detection of cell surface or microenvironment biomarkers, which could advance early cancer detection. Likewise, when combined with appropriate therapeutic agents and ultrasound-mediated deployment on demand, directly at the tumor site, these nanoparticles have been shown to contribute to improved therapeutic outcomes. Ultrasound's safety profile, broad accessibility and relatively low cost make it an ideal modality for the changing face of healthcare today. Aided by the multifaceted nano-sized contrast agents and targeted theranostic moieties described herein, ultrasound can considerably broaden its reach in future applications focused on the diagnosis and staging of cancer.
“…The use of nanobubbles [29,[278][279][280][281][282][283][284][285][286] as US contrast agents is in constant progress. Even if named nanobubbles they are typically in the range 150 to 1000-nm in diameter.…”
Section: Ultrasound (Us)mentioning
confidence: 99%
“…Regardless of composition, surface functionalization of the nanomaterial is required to enable targeting and stealth for long circulation times with minimal nonspecific binding [239]. There is a plethora of entities that can be incorporated onto a NP's surface, with covalent bonding preferred over electrostatic interactions: DNA, RNA, [472] oligonucleotides (aptamers), [29,434,[473][474][475][476] peptides, [36,175,201,[477][478][479][480][481][482] proteins, [483][484][485][486][487] enzymes, [488][489][490][491] antibodies [492]. No matter what the surface moiety, its activity must not be altered once anchored to the NP surface ( Figure 13).…”
Section: Functionalizationmentioning
confidence: 99%
“…Clinical Imaging modalities generally include complementary techniques [14] such as: optical imaging, [15][16][17][18][19][20][21][22][23] magnetic resonance imaging (MRI), [24][25][26][27] computed tomography (CT), [28] ultrasound imaging (USI) [29][30][31][32][33] positron emission tomography (PET) [34][35][36][37] and single photon emission computed tomography (SPECT) [38][39][40]. Other techniques are also scrutinized, for example multi-photon plasmon resonance microscopy, [41] optical coherence tomography (OCT), [42] surface enhanced Raman spectroscopy (SERS), [15,[43][44][45][46][47] and diffuse optical spectroscopy [48].…”
The successful development of nanomaterials illustrates the considerable interest in the development of new molecular probes for medical diagnosis and imaging. Substantial progress was made in synthesis protocol and characterization of these materials whereas toxicological issues are sometimes incomplete. Nanoparticle-based contrast agents tend to become efficient tools for enhancing medical diagnostics and surgery for a wide range of 2 imaging modalities. Multimodal nanoparticles (NPs) are much more efficient than conventional molecular-scale contrast agents. They provide new abilities for in vivo detection and enhanced targeting efficiencies through longer circulation times, designed clearance pathways, and multiple binding capacities. Properly protected, they can safely be used for the fabrication of various functional systems with targeting properties, reduced toxicity and proper removal from the body. This review mainly describes the advances in the development of mono-to multimodal NPs and their in vitro and in vivo relevant biomedical applications ranging from imaging and tracking to cancer treatment. Besides specific applications for classical imaging, (MRI, PET, CT, US, PAI) are also mentioned less common imaging techniques such as terahertz molecular imaging (THMI) or ion beam analysis (IBA).Perspectives on multimodal theranostic NPs and their potential for clinical advances are also mentioned.
Starting from the general definition of hybrid nanomaterials, the introductory section will draw the readers' attention to the main issues concerning the use of fluorescent probes for in vitro and in vivo bioimaging and the general requirements for "the optimal probe". The benefits arising from the use of hybrid materials will be outlined especially concerning: 1 Non porous Fluorescent Silica nanoparticles. 2 Mesoporous silica based nanoparticles and Fluorescent Organosilicas. 3 Zeolites. In this section the recent advances in the preparation and characterization of nanosized zeolite crystals will be reviewed; different strategies of incorporation of fluorescent compound will be considered.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.